Arcadia Biosciences (NASDAQ:RKDA) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of Arcadia Biosciences (NASDAQ:RKDA) in a report released on Monday morning. The firm issued a sell rating on the basic materials company’s stock.

Separately, HC Wainwright restated a buy rating and issued a $10.00 price objective on shares of Arcadia Biosciences in a report on Friday, April 5th.

Arcadia Biosciences Stock Performance

Shares of RKDA stock opened at $2.05 on Monday. The stock has a market capitalization of $2.79 million, a P/E ratio of -0.15 and a beta of 0.60. The company has a 50 day moving average price of $2.33 and a 200 day moving average price of $2.71. Arcadia Biosciences has a fifty-two week low of $1.85 and a fifty-two week high of $7.30.

Arcadia Biosciences (NASDAQ:RKDA) last announced its quarterly earnings data on Thursday, March 28th. The basic materials company reported ($2.48) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.68) by $0.20. The firm had revenue of $1.17 million during the quarter, compared to analysts’ expectations of $1.80 million. Arcadia Biosciences had a negative net margin of 246.80% and a negative return on equity of 81.56%. On average, research analysts forecast that Arcadia Biosciences will post -5.01 EPS for the current fiscal year.

About Arcadia Biosciences

Arcadia Biosciences, Inc produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring.